Trials / Completed
CompletedNCT02838342
Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Besancon · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the potential immunomodulatory synergy of the association of metronomic cyclophosphamide (CMC) and interferon-alpha (IFN-alpha).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metronomic cyclophosphamide | 50 mg oral tablet, one tablet per day, every day for 6 months; abort if progression or intolerance |
| DRUG | Interferon-alpha | 3 months of treatment from the 4th cycle metronomic cyclophosphamide : subcutaneous injection, initial dose of 3 MIU three times a week. The dose may be adjusted as tolerated to achieve a T cell counts greater than 500 / mm3 |
Timeline
- Start date
- 2015-05-19
- Primary completion
- 2020-04-01
- Completion
- 2021-06-29
- First posted
- 2016-07-20
- Last updated
- 2021-08-02
Locations
2 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02838342. Inclusion in this directory is not an endorsement.